Patents by Inventor Matthew Whitters

Matthew Whitters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-21 RECEPTOR KNOCKOUT ANIMAL AND METHODS OF USE THEREOF
    Publication number: 20100223685
    Abstract: A transgenic non-human mammal with a disruption in its IL-21 receptor gene is provided, along with methods of using the transgenic non-human mammal.
    Type: Application
    Filed: January 6, 2010
    Publication date: September 2, 2010
    Inventors: Marion KASAIAN, Matthew WHITTERS, Andrea WURSTER, Mary COLLINS, Deborah YOUNG, Michael GRUSBY
  • Methods and compositions for modulating T helper (T) cell development and function
    Patent number: 7731946
    Abstract: Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: June 8, 2010
    Assignees: Wyeth LLC, The President and Fellows of Harvard College
    Inventors: Michael J. Grusby, Andrea Wurster, Deborah Young, Mary Collins, Matthew Whitters
  • Methods of using antibodies to human IL-13bc for inhibiting IL-13 binding
    Patent number: 7674591
    Abstract: Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
    Type: Grant
    Filed: February 27, 2006
    Date of Patent: March 9, 2010
    Assignee: Genetics Institute, LLC
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
  • METHODS AND COMPOSITIONS FOR MODULATING T HELPER (Th) CELL DEVELOPMENT AND FUNCTION
    Publication number: 20090197803
    Abstract: Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level.
    Type: Application
    Filed: November 12, 2007
    Publication date: August 6, 2009
    Inventors: MICHAEL J. GRUSBY, ANDREA WURSTER, DEBORAH YOUNG, MARY COLLINS, MATTHEW WHITTERS
  • Methods and compositions for modulating T helper (Th) cell development and function
    Patent number: 7314623
    Abstract: Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level.
    Type: Grant
    Filed: July 15, 2003
    Date of Patent: January 1, 2008
    Assignee: Wyeth
    Inventors: Michael J. Grusby, Andrea Wurster, Deborah Young, Mary Collins, Matthew Whitters
  • Cytokine receptor chain
    Publication number: 20060177902
    Abstract: Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
    Type: Application
    Filed: February 27, 2006
    Publication date: August 10, 2006
    Applicant: Genetics Institute, Inc.
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
  • Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
    Patent number: 7078494
    Abstract: Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
    Type: Grant
    Filed: November 16, 2000
    Date of Patent: July 18, 2006
    Assignee: Genetics Institute, LLC
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
  • Antagonizing interleukin-21 receptor activity
    Publication number: 20060039902
    Abstract: Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE).
    Type: Application
    Filed: August 5, 2005
    Publication date: February 23, 2006
    Inventors: Deborah Young, Mary Collins, Kyriaki Dunussi-Joannopoulos, Richard O'Hara, Marion Kasaian, Matthew Whitters
  • Cytokine receptor chain
    Publication number: 20050277126
    Abstract: The present invention is directed to methods for treating asthma.
    Type: Application
    Filed: November 15, 2004
    Publication date: December 15, 2005
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood, Marsha Wills-Karp
  • Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
    Publication number: 20050096268
    Abstract: Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.
    Type: Application
    Filed: September 25, 2003
    Publication date: May 5, 2005
    Inventors: Thomas Wynn, Monica Chiaramonte, Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
  • GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
    Publication number: 20050014224
    Abstract: The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.
    Type: Application
    Filed: May 24, 2004
    Publication date: January 20, 2005
    Inventors: Mary Collins, Ethan Shevach, Rebecca McHugh, Matthew Whitters, Deborah Young, Michael Byrne, Padmalatha Reddy, Geoffrey Stephens, Beatriz Carreno
  • Methods and compositions for modulating T helper (Th) cell development and function
    Publication number: 20040136954
    Abstract: Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level.
    Type: Application
    Filed: July 15, 2003
    Publication date: July 15, 2004
    Inventors: Michael J. Grusby, Andrea Wurster, Deborah Young, Mary Collins, Matthew Whitters
  • IL-21 receptor knockout animal and methods of use thereof
    Publication number: 20040016010
    Abstract: A transgenic non-human mammal with a disruption in its IL-21 receptor gene is provided, along with methods of using the transgenic non-human mammal.
    Type: Application
    Filed: April 17, 2003
    Publication date: January 22, 2004
    Inventors: Marion Kasaian, Matthew Whitters, Andrea Wurster, Mary Collins, Deborah Young, Michael Grusby
  • IL-13 Receptor chain
    Patent number: 6268480
    Abstract: IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: July 31, 2001
    Assignee: Genetics Institute, Inc.
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
  • Methods of inhibiting binding and treating Ig-mediated responses with IL-13 receptor
    Patent number: 6248714
    Abstract: IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor methods of mediating-Ig-responses and methods for their identification are also disclosed.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: June 19, 2001
    Assignee: Genetics Institute, Inc.
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
  • Methods of identifying inhibitors of binding of IL-13 to the IL-13 receptor chain
    Patent number: 6214559
    Abstract: Methods of identifying inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: April 10, 2001
    Assignee: Genetics Institute, Inc.
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
  • IL-13 cytokine receptor chain
    Patent number: 5710023
    Abstract: Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
    Type: Grant
    Filed: March 1, 1996
    Date of Patent: January 20, 1998
    Assignee: Genetics Institute, Inc.
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood